Dihexa: A Cautionary Tale Dihexa exemplifies the gap between preclinical hype and clinical reality
US20120245098A1 - Topical Palmitoyl Glutathione Formulations - Google Patents Topical Palmitoyl Glutathione Formulations Download PDF Info Publication number US20120245098A1 US20120245098A1 US13/072,277 US201113072277A US2012245098A1 US 20120245098 A1 US20120245098 A1 US 20120245098A1 US 201113072277 A US201113072277 A US 201113072277A US 2012245098 A1 US2012245098 A1 US 2012245098A1 Authority US United States Prior art keywords composition glutathione weight derivatives palmitoyl Prior art date Legal status (The legal status is an assumption and is not a legal conclusion
FDA's concerns include potential immunogenicity for certain administration routes, peptide-related impurities, and the fact that Ipamorelin acetate contains unnatural amino acids that add characterization complexity
Additionally, glutathione levels naturally decrease with age, partly due to a decline in the rate of synthesis
It gave rises to an imaginary in which the ever-increasing speed is associated with an idea of progress (Tomlinson, 2007)
A randomized trial comparing transurethral resection of the prostate, laser therapy and conservative treatment of men with symptoms associated with benign prostatic enlargement
